These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 336181

  • 1. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.
    Laucius JF, Bodurtha AJ, Mastrangelo JM, Bellet RE.
    Cancer; 1977 Nov; 40(5):2091-3. PubMed ID: 336181
    [Abstract] [Full Text] [Related]

  • 2. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H, Kolarić K, Malenica B, Nola P.
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [Abstract] [Full Text] [Related]

  • 3. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
    Berd D, Maguire HC, McCue P, Mastrangelo MJ.
    J Clin Oncol; 1990 Nov; 8(11):1858-67. PubMed ID: 2230873
    [Abstract] [Full Text] [Related]

  • 4. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D, Mastrangelo MJ.
    Cancer Invest; 1988 Nov; 6(3):337-49. PubMed ID: 3167614
    [Abstract] [Full Text] [Related]

  • 5. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS, Peters M.
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [Abstract] [Full Text] [Related]

  • 6. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
    Balzarini GP, Cascinelli N, Fontana V, Veronesi U.
    Tumori; 1974 Jun; 60(4):345-52. PubMed ID: 4439501
    [No Abstract] [Full Text] [Related]

  • 7. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, Prehn RT.
    Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
    [Abstract] [Full Text] [Related]

  • 8. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA, Gutterman JU, Burgess MA, Heilbrun LK, Murphy WK, Bodey GP, Stone E, Turner-Chism V, Hersh EM.
    Cancer; 1980 May 15; 45(10):2506-15. PubMed ID: 7378986
    [Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU, Mavligit GM, Reed R, Burgess MA, Gottlieb J, Hersh EM.
    Cancer Treat Rep; 1976 Feb 15; 60(2):177-82. PubMed ID: 769970
    [Abstract] [Full Text] [Related]

  • 10. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP, Labandter HP, Hiles RW, Bodenham DC.
    Br J Plast Surg; 1978 Oct 15; 31(4):317-22. PubMed ID: 361132
    [Abstract] [Full Text] [Related]

  • 11. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL, Richards F, Muss HB, Rhyne L, Cooper MR, White DR, Stuart JJ, Spurr CL.
    Cancer Treat Rep; 1978 Jul 15; 62(7):1085-7. PubMed ID: 356970
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
    Byrne MJ, Reynolds PM.
    Aust N Z J Med; 1982 Aug 15; 12(4):263-6. PubMed ID: 6958237
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB, Dent PB, Blajchman M, Muirhead WM, Price RA.
    Can Med Assoc J; 1977 Jul 09; 117(1):33-6. PubMed ID: 861909
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE, Peter HH, Schultheis W, Deicher H.
    Tumori; 1977 Jul 09; 63(3):303-7. PubMed ID: 898298
    [Abstract] [Full Text] [Related]

  • 19. Inconsistent response of B16 melanoma to BCG immunotherapy.
    Kreider JW, Bartlett GL, Purnell DM.
    J Natl Cancer Inst; 1976 Apr 09; 56(4):803-10. PubMed ID: 1255799
    [Abstract] [Full Text] [Related]

  • 20. Risks of BCG intralesional therapy: an experience with melanoma.
    Robinson JC.
    J Surg Oncol; 1977 Apr 09; 9(6):587-93. PubMed ID: 145518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.